Opinionated Science Episode 14: Cancer Immunotherapy: Vaccines, Viruses and Nobel Prizes

Podcast

Last Updated: March 26, 2021

(+ more)

Published: September 25, 2020

Opinionated Science Episode 14: Cancer Immunotherapy: Vaccines, Viruses and Nobel Prizes content piece image

Opinionated Science is Technology Networks’ homemade podcast, where our team of scientists-turned-journalists cut out the chewy jargon and serve up slices of the most fascinating stories from the world of science. Expect a new Opinionated Science every other Friday.

In this episode, the team explore cancer immunotherapy, a revolutionary set of treatments that has fundamentally changed cancer care. In exploring how our immune system can be turned against cancer, we follow a trail from ancient China to the cutting edge of medical research and look to a personalized future for immunotherapy. Opinionated Science is Technology Networks’ homemade podcast, where our team of scientists-turned-journalists cut out the chewy jargon and serve up slices of the most fascinating stories from the world of science.

Read more from this podcast:

Treating Cancer – 5 Types of Immunotherapy

Key Developments in Cancer Immunotherapy Over the Last Decade

Future Cancer Immunotherapy Treatments Could Be Administered by a Pill

Cancer and the Immune System

New Vaccine Has the Potential To Treat Several Different Cancers

Listen Now

Listen to more Technology Networks podcasts here.

Subscribe to Opinionated Science at your favorite podcast platform:

Listen here on Spotify.

Listen here on Apple Podcasts.

Meet the Authors

Laura Elizabeth Lansdowne

Managing Editor

Laura Lansdowne is the managing editor at Technology Networks, she holds a first-class honors degree in biology. Before her move into scientific publishing, Laura worked at the Wellcome Sanger Institute and GW Pharma.

RJ Mackenzie

RJ is a freelance science writer based in Glasgow. He covers biological and biomedical science, with a focus on the complexities and curiosities of the brain and emerging AI technologies. RJ was a science writer at Technology Networks for six years. RJ has a Master’s degree in Clinical Neurosciences from the University of Cambridge.